Recurrence-free or progression-free survival as a surrogate endpoint for overall survival in hepatobiliary-pancreatic cancers:would be associated with time change  

作　　者：Ning Peng Chuang Qin Shao-Ping Liu Jun-Liang Nong Teng-Meng Zhong Jian-Hong Zhong on behalf of the GUIDANCE investigators 

机构地区：[1]Department of Hepatobiliary Surgery,First Affiliated Hospital of Guangxi Medical University,Nanning,China [2]Department of Hepatobiliary Surgery,Liuzhou People’s Hospital,Liuzhou,China [3]Department of Hepatobiliary and Pancreatic Surgery,Eighth Affiliated Hospital of Guangxi Medical University,Guigang,China [4]Department of Hepatobiliary Surgery,Hengzhou City People’s Hospital,Hengzhou,China [5]Department of Hepatobiliary Surgery,People’s Hospital of Baise,Baise,China [6]Department of Hepatobiliary Surgery,Guangxi Medical University Cancer Hospital,Nanning,China [7]不详

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第6期1047-1050,共4页肝胆外科与营养(英文)

基　　金：supported by the Guangxi Key Research and Development Plan(GuiKe AB24010082);the First-class Discipline Innovation-driven Talent Program of Guangxi Medical University.

摘　　要：Hepatobiliary-pancreatic cancers mainly include hepatocellular carcinoma,biliary tract cancers,pancreatic ductal adenocarcinoma(PDAC),and colorectal liver metastases(CRLM)(1).Surgical resection is one of the curative treatment options for these tumors,but the proportion of patients who receive curative surgical treatment is not high.Many patients can only be treated systemically because their tumors are advanced stage.For patients receiving curative treatment,recurrence-free survival(RFS)and overall survival(OS)are the main evaluation outcomes.While for patients receiving systemic treatment,the main outcomes to evaluate the efficacy are progression-free survival(PFS)and OS.

关 键 词：Surrogate endpoint overall survival(OS) hepatobiliary-pancreatic cancers 

分 类 号：R73[医药卫生—肿瘤]